

Honduras

Region of the Americas





I. Epidemiological profile

Population (UN)	2016	%	Parasites and vectors
High transmission (> 1 case per 1000 population)	2,320,000	25	Plasmodium species: <i>P. falciparum</i> (33%), <i>P. vivax</i> (67%)
Low transmission (0-1 cases per 1000 population)	5,930,000	65	Major anopheles species: <i>An. albimanus</i> , <i>An. pseudopunctipennis</i> , <i>An. darlingi</i> , <i>An. cruzii</i> , <i>An. argyritarsis</i>
Malaria-free (0 cases)	858,000	9	Reported confirmed cases (health facility): 4,338 Estimated cases: 9,000 [7,000-11,140]
Total	9,113,000		Confirmed cases at community level: - Reported deaths: 0 Estimated deaths: ≤ 10


II. Intervention policies and strategies

Intervention	Policies/strategies	Yes/No	Adopted	Antimalarial treatment policy	Medicine	Year adopted					
ITN	ITNs/ LLINs distributed free of charge	Yes	2009	First-line treatment of unconfirmed malaria	-	-					
	ITNs/ LLINs distributed to all age groups	Yes	2012	First-line treatment of <i>P. falciparum</i>	CQ+PQ(1d)	2011					
IRS	IRS is recommended	Yes	-	Treatment failure of <i>P. falciparum</i>	SP	2011					
	DDT is authorized for IRS	No	-	Treatment of severe malaria	QN; AS	2011					
Larval control	Use of larval control recommended	Yes	-	Treatment of <i>P. vivax</i>	CQ+PQ(14d)	2011					
IPT	IPT used to prevent malaria during pregnancy	N/A	-	Dosage of Primaquine for radical treatment of <i>P. vivax</i>		0.25 mg/Kg (14 days)					
Diagnosis	Patients of all ages should receive diagnostic test	Yes	-	Type of RDT used		P.f + P.v specific (Combo)					
	Malaria diagnosis is free of charge in the public sector	Yes	-								
Treatment	ACT is free of charge for all ages in public sector	Yes	-	Therapeutic efficacy tests (clinical and parasitological failure, %)							
	The sale of oral artemisinin-based monotherapies (oAMTs)	Never allowed	-	Medicine	Year(s)	Min	Median	Max	Follow-up	No. of studies	Species
	Single dose of primaquine is used as gametocidal medicine for <i>P. falciparum</i>	Yes	-	Organophosphates	2016-2016	0.4	0.6	0.8	1	1	<i>An. albimanus</i>
	Primaquine is used for radical treatment of <i>P. vivax</i>	Yes	-	Carbamates	2013-2016	1	1	1	1	6	<i>An. albimanus</i>
	G6PD test is a requirement before treatment with primaquine	No	-	Pyrethroids	2013-2016	0.5	0.9	1	18	18	<i>An. albimanus</i>
	Directly observed treatment with primaquine is undertaken	No	-								
	System for monitoring adverse reactions to antimalarials exists	No	-								
Surveillance	ACD for case investigation (reactive)	Yes	-								
	ACD of febrile cases at community level (pro-active)	Yes	-								
	Mass screening is undertaken	Yes	-								
	Uncomplicated <i>P. falciparum</i> cases routinely admitted	No	-								
	Uncomplicated <i>P. vivax</i> cases routinely admitted	No	-								
	Foci and case investigation undertaken	No	-								
	Case reporting from private sector is mandatory	Yes	-								



III. Financing




IV. Coverage



V. Impact



Confirmed malaria cases per 1000 and ABER



Malaria admissions and deaths

